Obigen Pharma Inc. (TPEX:7876)
Taiwan · Delayed Price · Currency is TWD 37.70
+0.30 (0.80%)
At close: Sep 7, 2026
Obigen Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 143.1 | 87.37 | 148.86 | 204.54 | 427.41 |
Short-Term Investments | 183.7 | 427 | 608.7 | 739.3 | - |
Cash & Short-Term Investments | 326.8 | 514.37 | 757.56 | 943.84 | 427.41 |
Cash Growth | -50.02% | -32.10% | -19.74% | 120.83% | - |
Other Receivables | 88 | 84.98 | 76.62 | 1.23 | 0.03 |
Receivables | 88 | 84.98 | 76.62 | 1.23 | 0.03 |
Other Current Assets | 38.28 | 37.94 | 3.68 | 71.48 | 63.73 |
Total Current Assets | 462.9 | 637.29 | 837.87 | 1,017 | 491.17 |
Property, Plant & Equipment | 161.86 | 206.1 | 274.37 | 312.79 | 303.34 |
Other Intangible Assets | 605.73 | 626.76 | 668.82 | 707.2 | 748.43 |
Other Long-Term Assets | 12.88 | 13.99 | 13.12 | 16.18 | 8.68 |
Total Assets | 1,243 | 1,484 | 1,794 | 2,053 | 1,552 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accrued Expenses | 8.75 | 15.73 | 17.34 | 7.11 | 3.55 |
Current Portion of Leases | 12.27 | 15.09 | 14.8 | 13.77 | 6.73 |
Other Current Liabilities | 4.49 | 4.02 | 5.23 | 3.17 | 6.78 |
Total Current Liabilities | 25.51 | 34.83 | 37.37 | 24.05 | 17.06 |
Long-Term Leases | 46.1 | 66.08 | 81.16 | 95.96 | 49.69 |
Other Long-Term Liabilities | - | 0.55 | 0.55 | 0.56 | 0 |
Total Liabilities | 71.61 | 101.46 | 119.08 | 120.57 | 66.75 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 1,072 | 1,069 | 1,060 | 1,060 | 760.03 |
Additional Paid-In Capital | 1,522 | 1,511 | 1,488 | 1,470 | 770.43 |
Retained Earnings | -1,423 | -1,199 | -872.71 | -598.41 | -353.11 |
Comprehensive Income & Other | 0.33 | 1.3 | 0.24 | 0.24 | 307.53 |
Shareholders' Equity | 1,172 | 1,383 | 1,675 | 1,932 | 1,485 |
Total Liabilities & Equity | 1,243 | 1,484 | 1,794 | 2,053 | 1,552 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 58.37 | 81.16 | 95.96 | 109.73 | 56.42 |
Net Cash (Debt) | 268.43 | 433.21 | 661.6 | 834.11 | 370.99 |
Net Cash Growth | -52.51% | -34.52% | -20.68% | 124.83% | - |
Net Cash Per Share | 2.51 | 4.08 | 6.24 | 8.14 | 4.88 |
Filing Date Shares Outstanding | 107.23 | 106.92 | 106 | 106 | 76 |
Total Common Shares Outstanding | 107.23 | 106.92 | 106 | 106 | 76 |
Working Capital | 437.39 | 602.46 | 800.5 | 992.5 | 474.11 |
Book Value Per Share | 10.93 | 12.92 | 15.80 | 18.23 | 19.54 |
Tangible Book Value | 566.03 | 755.92 | 1,006 | 1,225 | 736.44 |
Tangible Book Value Per Share | 5.28 | 7.06 | 9.49 | 11.56 | 9.69 |
Machinery | 150.1 | 145.86 | 194.95 | 163.01 | 160.2 |
Construction In Progress | - | - | - | 9.72 | 26.76 |
Leasehold Improvements | 165.64 | 165.26 | 177.77 | 168.51 | 138.8 |